Key statistics
As of last trade, INmune Bio Inc (0Y2:BER) traded at 4.76, 12.26% above the 52 week low of 4.24 set on Oct 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.54 |
---|---|
High | 4.76 |
Low | 4.52 |
Bid | 4.60 |
Offer | 4.82 |
Previous close | 4.56 |
Average volume | 0.00 |
---|---|
Shares outstanding | 22.17m |
Free float | 15.80m |
P/E (TTM) | -- |
Market cap | 105.54m USD |
EPS (TTM) | -2.18 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 18:37 GMT.
More ▼
Announcements
- INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
- INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
- INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
- INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
- INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
- INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
- INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
- INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
- INmune Bio Announces $13.0 Million Registered Direct Offering
- INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
More ▼